Alembic Pharmaceuticals
Alembic Pharmaceuticals Share Price Chart
Alembic Pharmaceuticals last traded at ₹790.25 (2026-10-13). Over the past month the stock moved -3.6%, three months the stock moved +4.1%, year the stock moved -17.4%. Its closing range over 52 weeks is ₹655.95 – ₹937.50, with the latest close 15.7% below the high.
Closing prices up to 2026-10-13.
About Alembic Pharmaceuticals
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
Leading Pharma company The company is a leading research-driven, integrated pharmaceutical company specializing in generic formulations across diverse platforms. [1]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Alembic Pharmaceuticals reported sales of ₹2,150.00 crore (+25.7%) and net profit of ₹172.00 crore (+11.7%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 2,150 | 332.00 | 15.00 | 172.00 | 8.80 |
| Mar 2026 | 1,848 | 228.00 | 12.00 | 202.00 | 10.31 |
| Dec 2025 | 1,876 | 292.00 | 16.00 | 132.00 | 6.76 |
| Sep 2025 | 1,910 | 316.00 | 17.00 | 184.00 | 9.40 |
| Jun 2025 | 1,711 | 281.00 | 16.00 | 154.00 | 7.85 |
| Mar 2025 | 1,770 | 271.00 | 15.00 | 157.00 | 7.98 |
| Dec 2024 | 1,693 | 260.00 | 15.00 | 138.00 | 7.04 |
| Sep 2024 | 1,648 | 239.00 | 15.00 | 153.00 | 7.80 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +3.3% | +3.8% | +16.7% | +9.5% | +15.9% | +10.8% | +4.4% | +25.7% |
| Operating profit growth | +14.9% | -2.3% | +4.2% | +18.6% | +32.2% | +12.3% | -15.9% | +18.1% |
| Net profit growth | +11.7% | -23.3% | -11.8% | +14.1% | +20.3% | -4.3% | +28.7% | +11.7% |
| EPS growth | +12.2% | -23.3% | -12.0% | +14.6% | +20.5% | -4.0% | +29.2% | +12.1% |
| OPM % | 15.0% | 15.0% | 15.0% | 16.0% | 17.0% | 16.0% | 12.0% | 15.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Alembic Pharmaceuticals reported sales of ₹7,345.00 crore (+10.1%) and net profit of ₹671.00 crore (+15.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 7,345 | 1,118 | 15.00 | 671.00 | 34.33 |
| Mar 2025 | 6,672 | 1,008 | 15.00 | 582.00 | 29.68 |
| Mar 2024 | 6,229 | 932.00 | 15.00 | 616.00 | 31.33 |
| Mar 2023 | 5,653 | 682.00 | 12.00 | 342.00 | 17.40 |
| Mar 2022 | 5,306 | 874.00 | 16.00 | 521.00 | 26.50 |
| Mar 2021 | 5,393 | 1,480 | 27.00 | 1,146 | 58.33 |
| Mar 2020 | 4,606 | 1,223 | 27.00 | 801.00 | 43.97 |
| Mar 2019 | 3,935 | 874.00 | 22.00 | 583.00 | 31.00 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +25.7% | +17.1% | +17.1% | -1.6% | +6.5% | +10.2% | +7.1% | +10.1% |
| Operating profit growth | +35.9% | +39.9% | +21.0% | -40.9% | -22.0% | +36.7% | +8.2% | +10.9% |
| Net profit growth | +41.2% | +37.4% | +43.1% | -54.5% | -34.4% | +80.1% | -5.5% | +15.3% |
| EPS growth | +41.6% | +41.8% | +32.7% | -54.6% | -34.3% | +80.1% | -5.3% | +15.7% |
| OPM % | 22.0% | 27.0% | 27.0% | 16.0% | 12.0% | 15.0% | 15.0% | 15.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Alembic Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
USFDA completes inspection at Alembic Pharmaceuticals’ Bioequivalence Facility in Vadodara
-
Alembic Pharmaceuticals receives USFDA approval for Prucalopride Tablets - Business Standard
-
Alembic Pharmaceuticals moves up as its partner NATCO gets USFDA’s tentative nod for Olaparib Tablets
-
Alembic Pharmaceuticals' partner NATCO gets USFDA’s tentative nod for Olaparib Tablets
-
Alembic Pharmaceuticals receives USFDA final approval for Dapsone Gel - Business Standard
-
Alembic Pharmaceuticals receives USFDA approval for Binimetinib Tablets, 45 mg - Business Standard
-
Alembic Pharmaceuticals receives USFDA approval for Tretinoin Cream USP, 0.05% - Business Standard
-
Alembic Pharmaceuticals gets USFDA’s tentative nod for Larotrectinib Capsules
-
Alembic Pharmaceuticals gets USFDA's final approval for Haloperidol tablets
-
Alembic Pharmaceuticals receives USFDA approval for Haloperidol Tablets - Business Standard
Frequently Asked Questions
What is the share price of Alembic Pharmaceuticals today?
Alembic Pharmaceuticals shares were last quoted at ₹790.25 (-1.3% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a price-to-earnings (P/E) ratio of 24.48 and a price-to-book (P/B) ratio of 2.90. The industry P/E is 53.33.
What is the 52-week high and low of Alembic Pharmaceuticals?
The 52-week high of Alembic Pharmaceuticals is ₹998.00 and the 52-week low is ₹635.30.
What is the market cap of Alembic Pharmaceuticals?
The market capitalisation of Alembic Pharmaceuticals is about ₹16,975.19 crore.
How did Alembic Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Alembic Pharmaceuticals reported sales of ₹2,150.00 crore (+25.7%) and net profit of ₹172.00 crore (+11.7%), compared with the same quarter last year.
Is Alembic Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Alembic Pharmaceuticals has a 3-year ROE of 13.00%, 3-year profit growth of 28.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Alembic Pharmaceuticals?
Promoters hold about 69.87% of Alembic Pharmaceuticals.
Which sector does Alembic Pharmaceuticals belong to?
Alembic Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.